Lee's Pharmaceuticals (00950) is expected to account for net profit of approximately HK$85 million to HK$95 million for the medium term

According to the Zhitong Finance App, Lee's Pharmaceutical Company (00950) announced that the Group expects to obtain net profit attributable to unaudited shareholders of approximately HK$85 million to HK$95 million in the six months ending June 30, 2026, and approximately HK$67.2 million for the six months ending June 30, 2025.

The Group's interim results are expected to improve, mainly due to (i) an increase in the Group's earnings; (ii) an improvement in the Group's overall gross margin, which is due to a more ideal product portfolio, with high-profit specialty and imported products accounting for a relatively large share, and continuous improvement in manufacturing efficiency at the Group's production sites. The positive impact of the combination of these two factors was sufficient to offset the increase in research and development expenses, sales and distribution expenses, and administrative expenses (including costs associated with the Group's newly consolidated US business) during the reporting period.